Acquiring Company
Pulmatrix
Acquired Company
Eos SENOLYTIX
LexingtonHoustonHealthcareBiotechnologyHealth CareDescription
Pulmatrix, Inc. has announced a proposed merger with Eos SENOLYTIX, expected to close in the third quarter of 2026. The agreement aims to combine their resources to enhance the development of biopharmaceutical products. Pulmatrix has filed a Form S-4 as part of the merger process. If completed, Eos's business will continue under the combined entity.
Don't miss Pulmatrix's next move
Get an email the moment Pulmatrix makes an acquisition, hires an exec, or expands — usually minutes after it happens.
One email per event. Unsubscribe anytime.
Related People
M&A Insights
Based on deal dataFrequently asked
Who acquired Eos SENOLYTIX?
Eos SENOLYTIX was acquired by Pulmatrix, based in Lexington. The deal was reported on August 13, 2026. Pulmatrix is publicly traded (PULM) and operates in Healthcare.
When did Pulmatrix acquire Eos SENOLYTIX?
Pulmatrix's acquisition of Eos SENOLYTIX was reported on August 13, 2026. Pulmatrix, Inc. has announced a proposed merger with Eos SENOLYTIX, expected to close in the third quarter of 2026. The agreement aims to combine their resources to enhance the development of biopharmaceutical products. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Eos SENOLYTIX do?
Eos SENOLYTIX, Inc. is a biotechnology company specializing in the development of novel gerotherapeutic peptides aimed at targeting mitochondrial dysfunction in aging-related diseases. It is privately held, operating in Biotechnology, and is based in Houston.